Ibrutinib 560 mg

DRUG3 trials

Sponsors

Johnson & Johnson Private Limited, US Oncology Research, The Lymphoma Academic Research Organisation

Conditions

Breast NeoplasmsLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-CellMalignant Neoplasm of BreastMantle Cell Lymphoma

Phase 1

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Active, not recruitingNCT03379428

US Oncology ResearchBreast Neoplasms, Malignant Neoplasm of Breast

Start: 2017-11-29End: 2025-01-31Updated: 2024-12-06

Phase 2

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Active, not recruitingNCT04802590

The Lymphoma Academic Research OrganisationMantle Cell Lymphoma

Start: 2022-01-24End: 2030-03-02Updated: 2026-08-28

Phase 4

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

CompletedNCT03190330

Johnson & Johnson Private LimitedLeukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Start: 2019-06-26End: 2023-05-03Updated: 2025-05-25

Related Papers

A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer

Cancer Medicine2026-07-27

Ibrutinib, venetoclax plus CD20 monoclonal Ab: Initial results of OASIS II, a prospective randomized phase 2 trial in previously untreated mantle cell lymphoma patients.

Journal of Clinical Oncology2025-05-28

Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial

Blood2024-11-053 citations

5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial

Blood2024-11-052 citations

Abstract PO1-04-03: Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer

Cancer Research2024-05-02

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Blood2024-04-2515 citations

P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.

HemaSphere2023-08-012 citations